Please login to the form below

Not currently logged in
Email:
Password:

Greg Perry joins IFPMA as assistant director general

Will move to the global industry body from the Medicines Patent Pool

IFPMA Greg PerryThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has appointed Greg Perry to be its new assistant director general.

Perry, who was most recently executive director of the Medicines Patent Pool in Geneva, will move to the global industry body in February.

He has more than 20 years’ leadership and advocacy experience in the public healthcare arena, most recently as executive director of the Medicines Patent Pool, in Geneva.

Prior to his time at the Medicines Patent Pool, which he joined in 2013, Perry spent 14 years as director general of the European Generic Medicines Association.

Thomas Cueni, IFPMA director general, said: “I am very pleased to have someone with such depth of experience and recognised track record joining our leadership. Greg has proven capabilities on a broad range of issues and will help us to cross bridges and reach out to multiple stakeholders equally interested to drive global health progress for the benefit of patients.”

At the IFPMA he will have responsibility for its external outreach and stakeholder engagement on global health topics such as innovation, access, and the international regulatory environment.

Perry said: “I will be joining IFPMA at an exciting time - where the role of the of the private sector as a major player in achieving universal healthcare is now regarded as essential. I have worked in a range of roles in the healthcare arena during the course of my career, but universal health care has been at the core of all of them.”

22nd December 2017

From: Regulatory

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins Insights

Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...